Non-Randomized, Single-Center Pilot Trial Assessing The Safety/Efficacy Of Targeting Peripheral And Central Humoral Alloimmune Memory With Daratumumab And With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
Latest Information Update: 20 May 2022
Price :
$35 *
At a glance
- Drugs Belatacept (Primary) ; Daratumumab (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms COMBAT
- 12 May 2022 Status changed from not yet recruiting to recruiting.
- 08 Dec 2021 New trial record